Association of Middle Molecules Clearance With HDF Volume

Launched by EAST AND NORTH HERTFORDSHIRE NHS TRUST · Jul 17, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a specific dialysis technique called hemodiafiltration (HDF) may improve the health and survival of patients with end-stage renal disease, particularly focusing on the clearance of a substance called beta-2-microglobulin. Researchers believe that using a higher volume of HDF could help remove this substance from the blood more effectively, which may lead to better health outcomes. The goal of the study is to understand how the amount of fluid used in HDF relates to the clearance of beta-2-microglobulin, as this could help doctors tailor dialysis treatments to better meet individual patient needs.

To participate in this trial, individuals need to be at least 18 years old, have been receiving dialysis for at least three months, and have been on hemodiafiltration for over four weeks. Participants will undergo assessments to measure their levels of beta-2-microglobulin during HDF treatments. This study is important because it could simplify how doctors evaluate kidney function in dialysis patients and potentially improve treatment strategies for a broader range of individuals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years or above.
• • Ability to give informed consent.
• • End stage renal failure treated by dialysis for at least 3 months.
• • Established on hemodiafiltration for \>4 weeks.
• • Prognosis more than 6 months as assessed by PI
• Exclusion Criteria:
• • Age less than 18 years.
• • Inability to give informed consent.
• • Prognosis less than 6 months as assessed by PI